Hemoglobin β-F41K: A recombinant oxygen carrier prototype engineered for enhanced heme retention, stability, and optimal oxygenation properties
Journal of Biological Chemistry · 2025-08 · 301 (8) · 110477
DOI: 10.1016/j.jbc.2025.110477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-08. Verfasst von Mohd Asim Khan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Delhi South Campus, New Delhi, India. Hauptthemen laut MEDLINE: Heme, Oxygen, Protein Engineering, Hemoglobins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the National Institutes of Health, National Institutes of Health, Life Sciences Research Board.
Abstract (Originalsprache)
Recombinant hemoglobin-based oxygen carriers (rHBOCs) have several potential advantages as blood substitutes in transfusion medicine, especially in emergency situations. However, the wide use of rHBOCs in humans has been limited by challenges including hypertension due to nitric oxide scavenging, autoregulatory responses, and rapid heme dissociation. Among these, heme dissociation remains a critical unresolved issue, as it leads to toxicity and compromises oxygen delivery efficiency. Heme retention in the globin moiety is a key problem that needs to be solved to develop recombinant HBOCs as safe transfusion agents. Here, we report the results of protein engineering experiments to enhance heme retention and thermal stability with the aim of designing stable HBOCs. We successfully introduced a mutation into recombinant human Hb0.1 (rHb0.1), named β-F41K, that significantly reduced rates of heme dissociation and auto-oxidation while simultaneously maintaining thermal stability and oxygen affinity at levels well suited to respiratory gas transport in vivo. The higher rate of heme retention in recombinant Hb0.1 β-F41K makes this protein an especially promising HBOC prototype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Delhi South Campus, New Delhi, India.
- School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, USA.
- Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, Delhi, India.
- Department of Biochemistry, University of Delhi South Campus, New Delhi, India; Department of Biological Sciences, Birla Institute of Technology and Science Pilani, K K Birla Goa Campus, Goa, India. Electronic address:…
Förderung
- Foundation for the National Institutes of Health
- National Institutes of Health
- Life Sciences Research Board
- University of Delhi
- Defence Research and Development Organisation
- Government of India Department of Biotechnology
- Rice University
- University Grants Commission
Zitieren
APA
Khan, M. A., Yadav, K., Signore, A. V., Mittal, N., Uppal, S., Tyagi, A. K., Mittal, G., Storz, J. F., & Kundu, S. (2025). Hemoglobin β-F41K: A recombinant oxygen carrier prototype engineered for enhanced heme retention, stability, and optimal oxygenation properties. Journal of Biological Chemistry, 301(8), 110477. https://doi.org/10.1016/j.jbc.2025.110477
Vancouver
Khan MA, Yadav K, Signore AV, Mittal N, Uppal S, Tyagi AK, et al. Hemoglobin β-F41K: A recombinant oxygen carrier prototype engineered for enhanced heme retention, stability, and optimal oxygenation properties. Journal of Biological Chemistry. 2025;301(8):110477. doi:10.1016/j.jbc.2025.110477
BibTeX
@article{Khan2025,
author = {Khan, Mohd Asim and Yadav, Kajal and Signore, Anthony V and Mittal, Nidhi and Uppal, Sheetal and Tyagi, Amit K and Mittal, Gaurav and Storz, Jay F and Kundu, Suman},
title = {Hemoglobin β-F41K: A recombinant oxygen carrier prototype engineered for enhanced heme retention, stability, and optimal oxygenation properties},
journal = {Journal of Biological Chemistry},
year = {2025},
volume = {301},
number = {8},
pages = {110477},
doi = {10.1016/j.jbc.2025.110477}
}
EUVIMED